Recce Pharmaceuticals Wins $2M Defense Grant For Revolutionary Burn Treatment
Recce Pharma awarded $2M DoD grant for RECCE 327 Gel, advancing burn wound infection treatment.
Recce Pharmaceuticals Ltd has been awarded a $2 million grant by the U.S. Department of Defense to accelerate the development of its RECCE 327 Gel, aimed at treating burn wound infections and preventing sepsis in military environments. This grant will facilitate the assessment of RECCE 327 Gel as a viable alternative to conventional antimicrobial dressings. Coupled with a successful A$8 million institutional placement and an open share purchase plan, this funding underscores Recce’s expanding impact in the medical sector and its dedication to enhancing health outcomes.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Ab Science révise les calendriers d'essais après trois inspections GCP
Novo Nordisk signe un accord de 2,6 milliards $ avec Hengrui pour un GLP-1 oral
Discussion